KBI Biopharma, a JSR Life Sciences company and global cGMP contract development and manufacturing organisation (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.
JB brings more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody drug conjugates (ADCs) and the latest advancements in cell and gene therapies.
With a proven track record of implementing winning sales strategies and cultivating high-performing teams, JB will lead KBI’s global business development initiatives, driving the company towards continued growth and sustained success.
This pivotal role is focused on building and maintaining long lasting partnerships with KBI’s current and future customers around the globe. JB’s commitment to fostering relationships with external partners and internal team members alike is a value that aligns well with KBI’s collaborative culture.
“His servant leadership philosophy will further fortify our team, propelling KBI to new heights.” Remarked J.D. Mowery, President & CEO of KBI Biopharma.
Before joining KBI, JB held leadership roles in business development at AGC Biologics, Ajinomoto Bio-Pharma Services, Novasep and Isochem. He holds a Master of Science in Chemical Engineering from Centrale Marseille.
